期刊文献+

分泌性白细胞蛋白酶抑制因子在结肠癌中的表达及其临床意义 被引量:2

Expression and clinical significance of secretory leucocyte protease inhibitor in colon carcinoma
下载PDF
导出
摘要 目的探讨结肠癌组织中白细胞蛋白酶抑制因子(SLPI)的表达及其临床意义。方法选择150例结肠癌及癌旁正常组织制成微阵列芯片作为研究对象,用免疫组织化学方法检测组织芯片中SLPI蛋白表达并评分,采用f检验比较不同SLPI表达水平和结肠癌临床病理f生特征,包括年龄、性别、组织分化程度、TNM分期、淋巴结转移及远处转移之间的关系。结果SLPI在结肠癌组织中相对于正常结肠组织高表达,SLPI蛋白高表达与肿瘤分化[低分化:8(42.1%)”s11(57.9%);中腐分化:3(2.3%)w128(97.7%)、TNM分期:[Ⅲ~Ⅳ:25(29.4%)口s60(70.6%)]、Ⅰ~Ⅱ:2(3.1%)郴63(96.9%)、淋巴结转移[18(28.6%)w45(71.4%)]及远处转移[11(84.6%)傩2(15.4%)]相关(P〈O.05),而与患者的性别和年龄差异无统计学意义(P〉0.05)。结论SLPI表:g_Jk平与肿瘤分化程度、TNM分期、淋巴结转移及远处转移有关,有可能作为判断结肠癌患者预后的指标。 Objective To investigate the expression of secretory leucocyte protease inhibitor (SLPI) in colon cancer and their clinical significance. Methods Immunohistochemistry was performed to detect the SLPI expression in colon cancer tissue microarray. The expression of SLPI was scored by two pathologists and was analyzed using Ks test to explore its influence on the pathologic characteristics of colon carcinoma. Results SLPI was up-regulated in colon cancer tissue compared to normal mucosa. Overexpression of SLPI protein was correlated with differentiation grade (low differentiation: 42.1% vs 57.9%; moderate/well differentiation: 2.3% vs 97.7%, TNM stages( Ⅲ-IV :29.4% vs 70.6%; Ⅰ - Ⅱ:3.1% vs 96.9%), lymph node metastasis (28.6% vs 71.4%) and distant metastasis (84.6% vs 15.4%), but not with patient age or sex. Conclusion SLPI overexpression correlates with aggressive pathologic characteristics of colon cancer and it may server as prognostic factor of colon cancer patients. Further research will be carried out to verify whether SLPI can become a new target for colon cancer treatment.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2013年第6期898-901,共4页 Journal of Southern Medical University
基金 厦门市海沧区科技局科技计划项目(350205Z20084003)
关键词 分泌性白细胞蛋白酶抑制因子 组织芯片 结肠肿瘤 免疫组织化学 secretory leucocyte protease inhibitor tissue microarray colonic neoplasms immunohistochemistry
  • 相关文献

参考文献11

  • 1Wang N, Thuraisingam T, Fallavolita L, et al. The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factorreceptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response [J]. Cancer Res, 2006, 66(6): 3062-70. 被引量:1
  • 2朱明华.组织微阵列及其在肿瘤病理研究中的应用[J].中华病理学杂志,2002,31(1):72-74. 被引量:26
  • 3King C, Cuatrecasas M, Castells A, et al. LIN28B promotes colon cancer progression and metastasis. [J]. Cancer Res, 2011, 71(12): 4260-8. 被引量:1
  • 4Weldon S, McGarry N, Taggart C, et al. The role of secretory leucoprotease inhibitor in the resolution of inflammatory responses [J]. Biochem Soc Trans, 2007, 35(Pt 2): 273-6. 被引量:1
  • 5McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor[J]. Clin Invest, 1992, 90(4): 1296-301. 被引量:1
  • 6Nukiwa T, Suzuki T, Fukuhara T, et al. Secretory leukocyte peptidase inhibitor and lung cancer [J]. Cancer Sci, 2008, 99(5): 849-55. 被引量:1
  • 7Cheng WL, Wang CS, Huang YH, et al. Overexpression of a secretory leukocyte protease inhibitor in human gastric cancer [J]. Int J Cancer, 2008, 123(8): 1787-96. 被引量:1
  • 8Xuan Q, Yang X, Mo L, et al. Expression of the serine protease kallikrein 7 and its inhibitor antileukoprotease is decreased in prostate cancer[J]. Arch Pathol Lab Med, 2008, 132: 1796-801. 被引量:1
  • 9Hoskins E, Rodriguez-Canales J, Hewitt SM, et al. Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells[J]. Gynecol Oncol, 2011, 122(3): 656-62. 被引量:1
  • 10O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 24, 88 (2): 277-85. 被引量:1

二级参考文献16

  • 1Venter JC, Adams MD,Myers EW, et al. The sequence of the human genome. Science,2001,291:1304-1351. 被引量:1
  • 2Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med,1998,4:844-847. 被引量:1
  • 3Comp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest,2000,80:1943-1949. 被引量:1
  • 4Perrone EE,Theoharis C,Mucci NR, et al. Tissue microarray assessment of prostate cancer tumor proliferation in African-American and white men. J Natl Cancer Inst, 2000,92:937-939. 被引量:1
  • 5Bubendorf L,Kolmer M,Kononen J,et al. Hormone therapy failure in human prostate cancer:analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst,1999,91:1758-1764. 被引量:1
  • 6Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray secreening in renal cell carcinoma. Am J Pathol, 1999,154:981-986. 被引量:1
  • 7Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol, 2000, 157:787-794. 被引量:1
  • 8Welsh JB, Zarrinkar PP,Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A, 2001,98:1176-1181. 被引量:1
  • 9Sallinen SL,Sallinen PK,Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res,2000,60:6617-6622. 被引量:1
  • 10Schraml P,Kononen J,Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res,1999,5:1966-1975. 被引量:1

共引文献25

同被引文献9

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部